



“Innovative Medicines. Healthier Lives.”

FACTBOOK

2020/2021




Our Philosophy

The Pharmaceutical Research & Manufacturers Association (PReMA) is a non-profit organization representing research-based pharmaceutical companies that produce innovative medicines to combat previously incurable diseases and improve existing treatments.

PReMA works to encourage Thailand to become a part of the global pharmaceutical research and development process, creating innovation not only for our own enhanced social well-being and national economic benefits, but also for the benefit of the world community.

We are committed to the discovery and universal access to innovative medicines for healthier lives. We strive to be recognized as a partner with the people of Thailand in the never ending quest to provide sustainable health solutions for everyone.

“ Innovative Medicines. Healthier lives. ”



Contents

Improving the Quality of Life (QoL)
for Thai patients

1

Contributing to Thailand's
pharmaceutical landscape
and economy

2

Providing access to quality-assured
innovative treatments

3

Strengthening the biopharmaceutical
landscape in Thailand

4

Multi stakeholder Partnership:
all for one and one for all

5

Harmonizing of pharmaceutical
regulations and healthcare
integration

6

Our promise

7

List of PReMA members

8





Improving the Quality of Life (QoL) for Thai patients

During 2016-2020, PReMA member companies have brought over **300** innovative and effective treatment against the top 5 leading causes of death to Thai people, allowing public access to effective healthcare.

TOP 5 causes of death
in Thailand



Medicines marketed
by PReMA members

#1 **Cancer**
 **103** 

#2 **Cerebrovascular**
 **65** 

#3 **Pneumonia**
 **46** 

#4 **Ischemic heart disease**
 **77** 

#5 **Diabetes**
 **42** 



Contributing to Thailand's pharmaceutical landscape and economy

PReMA is a non-profit organization representing members who are primarily research-based pharmaceutical companies. In 2019, member companies provided:

- equal opportunity employment to nearly **9,000 personnel*** in the industry.
- combined revenue **186 billion baht**** of the pharmaceutical market.

Source: *2020 TH PReMA TRS Overview Report, **Department of business development 2019.



R&D expenditure and investment from the pharmaceutical industry continues to grow relentlessly reaching the value of over **11 Billion Baht in 2019.**

Source: WHO & IQVIA analysis.



1 THB = 2.9 THB

Every 1 baht invested in clinical trials generates 2.9 baht for the Thai economy.

Source: Executive Summary Strategic Roadmap for Clinical Research in Thailand 2018-2020



Providing access to quality-assured innovative treatments



Innovative Treatments

We have introduced more than **150** new innovative treatments into the Thai market over the last four years to relieve the burden of illness and improve the health of the Thai people These include...

- 27** **Anti-cancer drugs**
(1/3 are monoclonal antibodies or protein kinase inhibitors)
- 23** **Drugs for alimentary tract and metabolism**
- 13** **General systemic anti-infective drugs**

Beyond common diseases, we also help those suffering from rare diseases by developing several innovative treatments throughout the past decade for MPS, Gaucher disease, Fabry disease and Pompe disease.



Innovative Vaccines

Over the past 50 years, our vaccines protected the people of the nation from numerous life threatening and debilitating diseases including:


-  **Measles**
-  **Mumps**
-  **Rubella**
-  **Polio**
-  **Hepatitis A**
-  **Hepatitis B**
-  **Herpes zoster**
-  **Influenza**
-  **Dengue**
-  **Rotavirus**



Strengthening and supporting the biopharmaceutical research and development landscape in Thailand


Between 2016-2019 over **300,000** Thais were able to access the most advanced therapies available through their participations in clinical trials supported by PReMA members.

The number of industry-sponsored clinical trials has grown rapidly and exceeded **1,000 trials** mark in 2019.



Remark: No. of clinical trials shown here is cumulative number of trials as of each year during 2016-2019.

Top 5 therapeutic areas industry sponsored clinical trials in 2019





Multi-stakeholder Partnerships: all for one and one for all

Tackling Thailand Health Challenges



Medical Affairs Forum (Patient engagement Session)
29 August 2018



2019 Policy Direction of CSMBs and Public Procurement
25 February 2019



Cancer Care Roadmap Advisory Board Meeting
15 August 2019



APEC life Sciences Innovation Forum and Asia - Pacific Financial Forum Dialogue
5 November 2019

Fostering Research & Innovation Ecosystem



Health Innovation Alliance: Dinner Dialogue
Theme : Sustainable partnership & healthier Lives
12 November 2019



19th ThaiTECT Annual Meeting : Fostering Innovation through Life Sciences Research Ecosystem
29-30 August 2019



Crack the Mindset Webinar Series
27 August 2020



Bio Asia Pacific 2020
29 October 2020



Harmonizing pharmaceutical regulations and healthcare integration

Strengthening The Regulatory System



Regulatory Affairs Forum 2019
8 March 2019



APEC Good Registration Management (GRM)
28-30 October 2019

Ethics & Business Integrity



Thailand Stakeholder Forum for Ethical Collaboration : Pursuing a Consensus Framework
7 November 2019





Our promise

“ PReMA stands shoulder to shoulder with the people of Thailand in the quest to evolve the pharmaceutical landscape through science, collaboration and innovation to bring healthier lives for all. ”

Being patient centric

As one of the leading healthcare organization, PReMA seeks no profit and practice patient centricity by focusing on augmenting research and innovative treatment to support healthcare professionals in managing treatments and improving patient outcomes.

Partnership for greater healthcare outcome

We remain totally committed to collaborating with multiple healthcare industry stakeholders to improve the quality of life for Thai patients and provide access to research-based innovative treatments.

Strengthening the regulatory system

We will continue to harmonize regulations and create common principles and practices in the pharmaceutical sector to raise the bar, minimize access impediments, strengthen the competitive landscape and further continue to the health regulatory system for quality, safety and better health outcome.



List of PReMA members

Ordinary Members



MENARINI



Abbott



astellas



Bristol Myers Squibb™



Boehringer Ingelheim



Daichi-Sankyo



AURIGA



DKSH



Mitsubishi Tanabe Pharma (Thailand)



MSD

INVENTING FOR LIFE™



NOVARTIS



novo nordisk®



OLIC (Thailand) Limited

A member of Fuji Pharma group



PACIFIC HEALTHCARE



Pfizer



SANOFI



SERVIER



Sumitomo Pharmaceuticals (Thailand)



Otsuka



ZUELLIG PHARMA

Associate Members




ACLIRES



IQVIA



"This Report has been prepared by IQVIA with reasonable skill and care and is provided to PReMA on an "as is" basis, without any warranties of any kind. The contents of this Report are intended for general informational purposes only."



408/85 Phaholyothin Place Building,
19th Floor, Phaholyothin Road, Samsen nai,
Phayathai, Bangkok 10400 Thailand